Sonja Zweegman

Research interests

Publications

• Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2020.11.014

• Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30756-7

• Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

  British Journal of Haematology · 2021 · https://doi.org/10.1111/bjh.17338

• Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00428-9

• Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30099-5

• Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0876-z

• Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)31240-1

• Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)33003-4

• Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

  Journal of Hematology & Oncology · 2018 · https://doi.org/10.1186/s13045-017-0549-1

• Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

  The Lancet Haematology · 2017 · https://doi.org/10.1016/s2352-3026(17)30088-1

• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx096

• Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30189-4

• European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

  Haematologica · 2015 · https://doi.org/10.3324/haematol.2014.117176

• Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.57.9961

• Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

  Blood · 2015 · https://doi.org/10.1182/blood-2014-12-615187

• Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(13)70609-0

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.350

• Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.42.3863

• Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.39.6820

• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

  Blood · 2011 · https://doi.org/10.1182/blood-2011-06-358812

• Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

  Blood · 2010 · https://doi.org/10.1182/blood-2009-12-261032

Current projects

No projects listed.